Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group

• Iwata, Hiromitsu

• ISHIKAWA, Hitoshi

• Takagi, Masaru

• Okimoto, Tomoaki

• Murayama, Sigeyuki

• Akimoto, Tetsuo

• Wada, Hitoshi

• Arimura, Takeshi

• Sato, Yoshitaka

• Araya, Masayuki

• Mizoe, Jun-etsu

• GOSHO, Masahiko

• Nakamura, Katsumasa

• Shirato, Hiroki

• SAKURAI, Hideyuki

Bibliographic Information

Other Title

• Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese radiation oncology study group

Abstract

This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (<jats:styled-content style="fixed-case">PT ) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with <jats:styled-content style="fixed-case">PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The <jats:styled-content style="fixed-case">NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/<jats:styled-content style="fixed-case">mL ). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (<jats:styled-content style="fixed-case">bRFS ) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the <jats:styled-content style="fixed-case">NCCN classification was a significant prognostic factor for <jats:styled-content style="fixed-case">bRFS , but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that <jats:styled-content style="fixed-case">PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (<jats:styled-content style="fixed-case">UMIN 000025453) on <jats:styled-content style="fixed-case">PT for prostate cancer has just been initiated in order to define its role in Japan.

Journal

• Cancer Medicine

  Cancer Medicine 7 (3), 677-689, 2018-03

  WILEY

Keywords

• Cancer Research
• Radiology, Nuclear Medicine and imaging
• Oncology

Details

• CRID: 1050282677603593088
• NII Article ID: 120007134358
• DOI: 10.1002/cam4.1350
• ISSN: 20457634
• HANDLE: 2241/00151515
• Web Site: https://tsukuba.repo.nii.ac.jp/records/46234
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.1350
• Web Site: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1350
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN